Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 13/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5310022 | 0.93 | LTA4H (0.61) | LTA4HKDM4EPKMDGAT1CYP3A4 | |
| SCHEMBL5317785 | 0.87 | LTA4H (0.56) | LTA4HDGAT1 | |
| SCHEMBL5660796 | 0.87 | MAPT (0.64) | LTA4HKDM4EPKMALDH1A1GAA | |
| SCHEMBL5314749 | 0.86 | LTA4H (0.76) | LTA4HKDM4EPKMALDH1A1MAPT | |
| SCHEMBL5661221 | 0.83 | LTA4H (0.47) | LTA4HKDM4EPKMDGAT1CYP3A4 | |
| SCHEMBL5311020 | 0.81 | LTA4H (0.77) | LTA4HKDM4EPKM | |
| SCHEMBL5313205 | 0.81 | LTA4H (1.00) | LTA4HKDM4EPKM | |
| SCHEMBL5661210 | 0.81 | LTA4H (0.66) | LTA4HKDM4EPKMGAA | |
| SCHEMBL5658663 | 0.81 | KDM4E (0.79) | LTA4HKDM4EPKMALDH1A1GAA | |
| SCHEMBL5333260 | 0.79 | LTA4H (0.57) | LTA4HKDM4EPKMALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007079003-A2 | AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESSELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KDM4E 1019/4885PKM 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.